Chembio Diagnostics (CEMI)

Data from SEC filings
Employee count
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

We held our 2021 Annual Meeting of Stockholders on June 25, 2021. The board of directors solicited proxies pursuant to a proxy statement that we filed on May 13, 2021 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934. There was no solicitation in opposition to the board’s solicitation.

At the meeting, holders of common stock were asked to consider and vote upon the four proposals set forth below. Each share of common stock was entitled to one vote with respect to each matter submitted to a vote at the meeting. Shares of common stock representing 12,620,504, or 62.34% of the total votes attributable to all outstanding shares of common stock, were present in person or by proxy at the meeting.

The voting results reported below are final.

The matters considered and voted on by the stockholders at the meeting and the votes of the stockholders were as follows:

Proposal 1.Stockholders voted as follows with respect to the election of each of the nominees for director identified in the proxy statement:

NomineeForWithholdBroker Non-Votes
David W.K. Acheson6,218,403418,6855,983,416
David W. Bespalko6,183,939453,1495,983,416
Katherine L. Davis4,210,8232,426,2655,983,416
Richard L. Eberly5,445,6681,191,4205,983,416
John G. Potthoff5,276,6671,360,4215,983,416

As a result of this vote, each of the five nominees was elected as a director to serve until the 2022 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.

Proposal 2.Stockholders voted as follows with respect to approval of the amendment to the Chembio Diagnostics, Inc. 2019 Omnibus Incentive Plan:

ForAgainstAbstainBroker Non-Votes
Approval of amendment to the 2019 Omnibus Incentive Plan4,309,726

Proposal 3.Stockholders ratified the appointment of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2021, by the following vote:

ForAgainstAbstainBroker Non-Votes
Ratification of appointment of Ernst & Young LLP11,781,592359,566479,346

Proposal 4.Stockholders approved, on a non-binding advisory basis, the compensation paid to our executive officers in 2020, as disclosed in the 2021 proxy statement, by the following vote:

ForAgainstAbstainBroker Non-Votes
Advisory vote on 2020 executive compensation5,618,506814,997203,5855,983,416